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Abstract 
Medication review is an essential component of comprehensive falls assessment. A medication review by pharmacists can assist to 
identify and notify prescribers of medications that require adjustment or discontinuation. Beers Criteria and the Medication 
Assessment Index (MAI) are explicit and implicit inappropriate prescribing (IP) tools, respectively. While the Beers Criteria has been 
applied to falls prevention, the MAI has not.  Developing alternative falls prevention tools has been spurned by both the desire to 
overcome limitations of the Beers Criteria, coupled with the need for implicit criteria which includes consideration for patient –
specific clinical judgement. A literature search and review of the Beers Criteria and MAI tools revealed advantages and disadvantages 
of each. Using combined explicit/implicit falls assessment criteria using both the Beers Criteria and MAI as a framework, a falls 
specific inappropriate prescribing (FASPIP) tool for use in elderly hospitalized patients was developed. Validation of the FASPIP in the 
clinical setting is needed.  
 
 
Falls and recurrent falls are the leading cause of injury–
related death and the most common cause of nonfatal 
injuries and hospital trauma admissions among older adults 
[1]. Approximately 10% of fatal falls for older adults occur in 
the hospital setting [2]. From 2001 to 2008, the estimated 
number of fall-related hospitalizations in older adults 
increased 50% [3]. However, there is better evidence for falls 
prevention in the community versus hospital setting. The 
Joint Commission specifically requires that patients in 
hospitals and long term care facilities be assessed for fall 
risk...”including the potential risk associated with the 
patient’s medication regime *4+.” A National Patient Safety 
Goal to reduce the risk of patient harm resulting from falls 
has been established [4]. Further, the Centers for Medicare & 
Medicaid Services will no longer reimburse for preventable 
injuries from falls sustained by Medicare beneficiaries during 
their hospital stay. 
 
Inappropriate prescribing and polypharmacy are among the 
strongest risk factors for falls in the elderly [5].  Moreover, 
they are modifiable risk factors. Yet we lack an appropriate, 
specifically designed assessment tool to screen and detect 
inappropriate prescribing (IP). While several tools have been 
described for the purposes of assessing IP in general 
(Inappropriate Prescribing in the Elderly Tool (IPET) [6], the  
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Beers Criteria [7], the Medication Appropriateness Index 
(MAI) [8],  the Screening Tool of Older Persons’ Potentially 
Inappropriate Prescriptions (STOPP) [9], and Screening Tool 
to Alert Doctors to the Right Treatment (START)[10]), their 
validity is controversial, their adoption in clinical practice and 
health services research is heterogeneous and their 
applicability and benefit to falls prevention is uncertain.  
When used individually, these tools fail to provide an 
integrative framework for fall prevention which considers 
patient’s active complaints, other conditions and 
medications, and adverse drug effects [11]. In fact, no 
medication screening tools that have good diagnostic 
properties have been reported in the literature for fall risk in 
hospital patients [12]. Further efforts are warranted to 
improve existing tools and facilitate their usage in 
hospitalized patients. 
 
In this paper, we aim to critically review the two most 
frequently used tools to assess IP, the Beers criteria and the 
Medication Appropriateness Index (MAI), and using a 
structured framework develop a falls specific IP assessment 
tool (FASPIP). 
 
Beers Criteria  
The Beers Criteria are the most commonly and internationally 
used criteria to assess IP; having been adopted by various 
healthcare settings and incorporated into federal quality 
regulations and measures for managed care plans. The most 
recent Beers criteria list consists of 48 medications and 
medication classes (78 medications altogether) some of 
which contribute to the risk of falls through various 
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pharmacologic mechanisms, such as orthostasis, dizziness, 
decreased postural reflexes, extrapyramidal symptoms, 
drugging, myorelaxant effects, visual impairment, impaired 
cognition and sedation[7]. The Criteria also lists medications 
to be avoided in the presence of 20 conditions or diseases, 
not necessarily pertaining to falls. Also included in the Beers 
Criteria is a dose-related list, i.e., drugs that should not 
exceed a maximum dose. So the criteria include three 
categories: a general list, dose-related list and comorbidity 
list.  
 
Beers Criteria Advantages 
The Beers listing provides simple, easy to follow, 
reproducible, inexpensive to assess and explicit criteria for 
identifying IP.  Explicit measures are designed to be a 
standard that can be applied to all patients, computerized 
and easily assessed in large patient samples [13]. The criteria 
are adaptable to administrative datasets using computerized 
algorithms. The criteria were developed with consensus 
methodology using the Delphi method and are based on 
literature reviews.  Additionally, use of the criteria does not 
require information about the indication for the drug. 
 
Explicit “drugs to avoid” criteria have been applied to falls 
prevention, in part due to their easy applicability whereas 
tools such as the MAI are rarely applied due to their need for 
comprehensive clinical information interpreted by a skilled 
individual. Thus, the Beers Criteria are the most widely used 
falls-assessment tool and have been adopted for use in Long 
Term Care facilities in the U.S [13]. 
 
Beers Criteria Limitations 
Beers Criteria was developed to detect IP; it was not designed 
as a fall-specific tool.  Further, it was developed for a 
different health care system than hospitals, i.e., nursing 
homes. Medications are included on the list with little falls 
potential (e.g. ticlopidine, nitrofurantoin) and in some cases 
medications are inappropriately listed.  Although it provides 
an excellent foundation, there is a growing body of evidence 
regarding the limitations of the Beers Criteria, including 
limited reliability in the hospital setting. Several studies 
observed that the use of Beers Criteria alone misses a 
significant amount of IP [14]. Concerns have been raised 
about the generalizability of Beers criteria to falls prevention 
in the hospital setting.  Ackroyd-Stolanz noted that use of 
Beers Criteria alone for identifying older hospitalized patients 
at risk of falls failed to identify the vast majority of falls [15].  
The difference in potential IP between patients who fell and 
those who did not was nonsignificant (10.9% vs. 9.3%, p = 
0.27) [12].  Holguin-Hernandez noted the need to adapt and 
complement the Beers Criteria and that 25.1% of hospitalized 
patients received medications that can cause falls, not 
included in the Beers Criteria [16]. Others have observed a 
correlation between IP and falls [17]. 
 
Beers Criteria, originally developed in 1991 [18], and updated 
in 1997 [19] and 2002 [7], has not been updated in over 10 
years. The criteria are not an exhaustive list of all medications 
known to be associated with increased risk of falls (e.g. loop 
diuretics). A drug on the list may represent IP, not because of 
its risk for falls but because of its risk of ADR in general. In 
some cases, drugs on the list should be avoided generically 
(e.g. digoxin in doses > 125 mcg/day). In most cases no 
threshold (e.g. creatinine clearance or GFR) is provided to 
identify high risk patients.  In other cases, IP depends on the 
dosage or duration of treatment. Many drugs not listed in the 
criteria have subsequently been associated with a high 
incidence of falls in older patients. Some of these medications 
represent classes of medications not known at the time the 
criteria were developed. As new drugs were approved, the 
list was not updated. For example, evidence is building that 
SSRIs increase fall risk as much as the older tricyclic 
antidepressants [20]. Other agents have been removed from 
the U.S. market (e.g. guanidine, propoxyphene) or are older, 
outdated and not commonly used. Some of the drugs on the 
criteria are used more commonly outside the U.S.  
 
The criteria also omit other prescribing considerations such as 
dosing, duration of therapy, polypharmacy, drug interactions, 
or under use. For example, use of four or more medications 
has been linked with an increased risk of falls for older 
patients [21].  Beers Criteria does not consider the effect of 
combinations of medication classes, nor does the list include 
over-the-counter medications or herbal products. Since the 
listing is based on a literature review and consensus, not all 
the criteria are evidence-based or based on strong-empirical 
data linking them to falls. Additionally, being an explicit 
approach, Beers criteria does not account for a risk/benefit 
analysis based on patient-specific clinical judgments, thus 
determinations refer to “potentially” IP *12+.  
 
Medication Appropriateness Index (MAI) 
MAI is an implicit measure of medication appropriateness 
and the most comprehensive one to date.  MAI has been 
developed and tested in studies of elderly male patients ( > 
65 yrs old). Like the Beers Criteria, the MAI was developed to 
detect IP; it was not designed as a falls-specific tool. MAI uses 
10 criteria for each medication a patient is taking,  assessing  
medication indication, effectiveness, dosage, directions, drug-
drug interactions, drug-disease interactions, expense, 
practicality, duplication, and treatment duration (Table 1) . 
Each criterion is rated as “appropriate”, “marginally 
appropriate”, or “inappropriate” *8+*22+.  
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Table 1. MAI criteria (items)  [adapted from Reference 8] 
Questions to be rated for each medication 
Are there significant drug-drug interactions?  
Are there significant drug-disease interactions? 
Is there an indication for the drug? 
Is the drug effective for the indication?  
Is there unnecessary duplication with other drugs? 
Is the duration of therapy acceptable?  
Is the dosage correct?  
Are the directions correct?**  
Are the directions practical?**  
Is this drug the least expensive alternative compared with others of equal utility?** 
**The three questions to be deleted for our FASPIP. Also, questions regarding drug-drug and  
drug –disease interactions could be consolidated. 
 
Initially, the MAI was developed as an item-level analysis tool 
(i.e. for each of the ten criteria/items). Recognizing the need 
to assess IP more globally, a summated MAI score per 
medication was later developed using a weighting scheme 
[22]. The ratings generate a weighted score that serves as a 
summary measure of prescribing appropriateness ranging 
from 0 to 18 (0 = no item inappropriate; 18 = all items 
inappropriate). Given its versatility, MAI could be developed 
in the future, into a person-level summary, to reflect the total 
burden of inappropriate medication [22]. The critical 
elements of any assessment tools are validity, reliability and 
prediction of clinical outcomes.   
 
a.  Validity: Is MAI measuring what it is intended to 
measure? 
The validity of an instrument is of decisive importance for any 
tool used in clinical practice and research. MAI is a 
comprehensive instrument and formally testing its validity 
may represent a complex task.  Most papers discussing the 
validity of MAI invoke face validity and content validity. While 
these elements are valuable, it is important to keep in mind 
their definition. Face validity refers to expert opinions, 
supporting the value of a test. Content validity (rational 
validity) still refers to expert opinions, except that the 
opinions are analyzed statistically. Both terms refer to the 
degree to which the content of the items reflects the content 
domain of interest. In addition, concurrent validity (ability to 
distinguish between meaningful groups, tested versus a gold 
standard) and predictive validity (ability to predict health 
outcomes) are in general, important types of validity required 
for the scientific acceptance of a measurement tool.     
 
b.  Reliability:  If MAI is administered repeatedly, will it 
produce similar results?  
The reliability of MAI was tested in several studies. When 
tested by the originators of the MAI index, the inter-rater 
percent agreement was 93% with an overall all items Kappa 
statistic of 0.83. The intra-rater agreement at 2-4 months for 
drugs overall was 97% and the overall all items Kappa statistic 
was 0.92 [8]. Similar results were reported for the reliability 
of the summated MAI: inter-rater agreement as assessed by 
the intraclass correlation coefficient was 0.74; percent 
agreement was 59%, and intra-rater reliability at 2-4 months 
was 71% [22].  
 
It has to be noted that these MAI reliability studies had been 
performed by the originators of the index, in a single setting, 
with groups of elderly veterans from the Veterans Affairs 
General Internal Medicine Clinic in Durham, North Carolina. 
However, a measurement tool needs to be tested in various 
populations and settings, and generate consistent results, 
before being used universally. In a VA hospital setting, with 
investigators other than the originators, the inter-rater 
agreement on MAI for all drugs overall was 89%, and the 
kappa statistic was 0.59 [8]. In two European settings, with 
evaluators other than the scale’s developers, inter- rater 
reliability was modest and intra-rater reliability was good 
[23][24]. These results support the use of MAI as a reasonably 
reliable, precise instrument. 
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c.  Does MAI have the ability to detect change over
 
time in 
response to a pharmacist intervention? 
Several studies suggest that MAI is responsive to change over 
time in health services interventions. The MAI was the 
primary outcome in a randomized clinical trial evaluating the 
effect of pharmaceutical care from admission to discharge in 
geriatric patients. Patients in the intervention group were 
significantly more likely than control patients to have an 
improvement in the MAI score from admission to discharge 
(OR= 9,1;  95% confidence interval 4.2 -21.6), but notably, not 
in the Beers Criteria  [25]. MAI was responsive to change in 
another randomized clinical trial, where inappropriate 
prescribing scores declined significantly more in the 
pharmaceutical care group  than in the control group at 3 
months (decrease 24% versus 6%, respectively)  and the 
effect was sustained at 12 months (decrease 28% versus 5%). 
This MAI change translated into changes in adverse drug 
events rates [26]. Consistent results have been reported in 
studies conducted with various types of interventions, such 
as inpatient and outpatient geriatric clinic care programs [27], 
multidisciplinary team interventions [28] or in different 
settings, such as older adults undergoing first-time transfer 
from a hospital to a long-term care facility [29]. 
 
d.  Does MAI have predictive ability? Can MAI scores predict 
clinically significant health outcomes, such as adverse drug 
reactions, falls, fall–related injuries?  
To the authors’ knowledge no study to date has addressed 
the predictive ability of MAI for falls and very few studies 
have examined the association between MAI and other 
health outcomes.  Indeed at least two questions contained in 
the MAI tool have little relevance to falls. A study conducted 
in a VA hospital setting, found that the original MAI scoring 
was not associated with adverse drug reactions (ADR), after 
controlling for age, number of drugs and comorbidities; 
however, a modified MAI score (weighing more heavily the 
MAI criteria for which the clinical outcome is likely an ADR, 
significantly predicted the ADR risk (OR 1.13, 95% CI 1.02-
1.26). The Beers Criteria were not associated with ADR in this 
study [13].  In other studies, an unfavorable MAI score was 
indirectly associated with ADR [26] and with inadequate 
blood pressure control and increased usage of emergency 
room visits [30].  
 
 MAI Advantages  
The MAI has several advantages for IP assessment: it focuses 
on the patient, rather than on the drug (as opposed to the 
Beers Criteria); it is comprehensive and therefore potentially 
sensitive to detect meaningful IP, or disease; it addresses 
multiple components of prescribing appropriateness, and can 
be applied to every medication in the context of patient-
specific characteristics [31]. Moreover, MAI has been tested 
in both inpatient and ambulatory settings. While it is a 
judgment–based scale, MAI has a good to very good intra-
rater and inter-rater reliability performance, most likely 
supported by explicit definitions and instructions which allow 
for a standardization of the rating process [8].  Further 
improvements in its validity and reliability, by more in-depth 
instructions, have been suggested [32].  The MAI was last 
updated in 2010. 
 
MAI Limitations  
The
 
MAI, while rather comprehensive, is burdensome, as it 
can take up to
 
10 minutes per drug to apply the instrument 
and it requires
 
a well-trained health professional [8]. This may 
considerably limit the use of MAI in clinical and health care 
services research. For instance, in  studies drawing their 
samples from the EPOC  study population [33],  only half of 
the 532 patients were feasibly evaluated with the MAI 
instrument [13][34];  in consequence this contributed to the 
lack of statistical power to assess the association between 
MAI and adverse drug events.    
 
In spite of its depth of investigation, MAI is not fully 
comprehensive, critics noting that although ADR due to drug-
drug or drug-disease interactions are considered, MAI does 
not assess the full range of ADR, nor does it addresses their 
causality. Neither patient compliance nor underprescribing 
are assessed [22].  Whether these limitations are having an 
impact on falls prevention, remains a subject of discussion.  
 
Moreover, due to time constraints, MAI is difficult to adopt in 
routine universal clinical practice, and due to its complexity, 
MAI is difficult to apply on large prescribing databases. These, 
in turn, may considerably limit the MAI’s potential to improve 
the quality of prescribing on a large scale in the face of an 
ever growing population of elderly patients experiencing falls 
and falls-related injuries.  The advantages and disadvantages 
of Beer’s Criteria and MAI described in detail above are 
summarized in Table 2. 
 
The dilemma of diagnosing and preventing IP with tools such 
as implicit MAI, or explicit Beers Criteria, raises the question 
whether we should approach the problem with a different 
perspective. The question is not whether to use an explicit or 
an implicit medication appropriateness tool. The two types of 
tools serve different purposes. Explicit and drug-oriented 
criteria or indicators which are independent of patient 
characteristics, have good reliability, are easy to use, and are 
easily coded in large administrative databases. Yet, it is 
questionable whether prescribing quality can be improved 
based on such limited prescription data alone [35][36][37].  
Implicit and patient-oriented criteria are more 
comprehensive, allowing medication evaluations in the 
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context of patient characteristics (diagnosis, comorbidity, etc) 
and while extremely time consuming, they have the highest 
likelihood to optimize the therapeutic management of the 
patients.  
 
Methodology 
A search for English-language articles was conducted in 
PubMed, Ovid, Scopus, Google Scholar and the Cochrane 
Central Register of Controlled Trials (2000-2011) using a 
combination of keywords: elderly, falls, inappropriate 
medications, hospital, Beers Criteria, Medication 
Appropriateness Index, MAI, aged, for literature identifying 
medications implicated in falls for older patients, free text, 
and links to related articles. A manual search of the reference 
lists of retrieved articles and reviews was conducted to 
identify additional publications. Secondary references from 
all authoritative reviews were identified. Using the Beers 
Criteria as a framework for development of a FASPIP, 
modifications were made to include medications if they 
appeared in peer-reviewed articles as implicated in falls for 
older patients.  Papers were not limited to those pertaining to 
falls in hospitalized patients. 
 
Our critical review of the MAI tool revealed its utility in 
identification of not merely unnecessary drugs 
(polypharmacy) but rather inappropriate medication usage 
based on indication, efficacy, drug-drug or drug-disease 
interaction, dosage, duration or therapeutic duplication. We 
then undertook revision of the MAI tool, omitting questions 
which had no relevance to fall assessment.   
 
Results 
The systematic literature review revealed a small number of 
primary research studies that have investigated the use of 
Beers Criteria for fall-related injury prevention. No studies 
have evaluated the MAI tool for falls. Various classes of 
medications have been examined in the literature.  
 
Based on the literature, we developed a comprehensive list of 
medications associated with falls. This list is intended to be 
updated as new medications are either approved by FDA or 
identified in the literature as causing falls (Table 3).  The list 
was alphabetized for ease of use. Omitted were drugs which 
do not necessarily increase the potential for falls but rather 
may increase harm from falls (e.g. bleeds from 
anticoagulants). Drugs that are currently rarely used clinically 
were omitted. Several drugs which have been removed from 
the U.S. market were also omitted. The list has been designed 
to be used in tandem with the revised MAI tool. Unlike 
previous tools, our tool includes OTC and herbal products 
reported in the literature. The list is not designed to include 
all drugs which can cause falls. Rather, it includes the more 
common medications implicated in falls in day to day clinical 
practice. The comorbidity list of Beer’s criteria and portion of 
the Beer’s criteria list pertaining to “drugs that should 
generally be avoided in the elderly” were considered too 
restrictive and cumbersome to use and not reflective of “real 
world” prescribing practices.  Some drugs, while 
inappropriate overall, might be necessary in given clinical 
situation. Our list does not contain these sections at all. Our 
list is simply an alphabetized list of medications which have 
been associated with falls in the literature or prescribing 
information. 
 
For the MAI, we attempted to simplify the tool to reduce the 
time involved to complete per patient. Three questions 
pertaining to cost of medication, and correctness or 
practicality of directions were omitted. Thus, the MAI was 
shortened to 7 questions only. 
 
Discussion 
Inappropriate prescribing is a complex problem, requiring 
complex solutions. Addressing its causes is important. 
Patients, prescribers and the environment in which 
prescribers operate constitute the main targets of action [38]. 
While the optimization of the  training of the prescribers and 
of the communication between prescribers and pharmacists 
are both  essential, in an environment with an ever increasing 
information base , dealing with an ever increasing complexity, 
quality checks and improvements will only grow in their 
importance.   Information technology holds a great promise. 
It has been suggested that prescribing in the future will use 
three interacting databases- the patient’s drug history, an 
evidence- based drug information and guidelines databases, 
and clinical information repositories [38] [39] [40].  
 
However, for the time being, we need immediate tools to 
deal with IP among elderly patients at increased risk for falls. 
Given the magnitude of falls events in the geriatric 
population, we need an effective and feasible screening tool 
and a comprehensive remediation approach.  The sequential 
integration of implicit criteria (such as MAI) with explicit 
criteria (such as updated Beers criteria) may be one of the 
options.  Such an approach would entail development and 
validation of a FASPIP, which should be user friendly and time 
efficient; this tool would identify patients in which a more in-
depth, comprehensive medication assessment is needed, and 
for which higher intensity fall prevention measures are 
required (Figure 1).  In spite of its advantages, as outlined 
above, MAI is not a screening tool, per se; MAI or similar 
comprehensive indices for medication review may serve 
however, as a gold standard, against which to test other 
screening tools.    
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Figure 1 
Screening:  
Medication Fall Risk Score; 
Modified Beers Criteria 
List 
Prescriber Feedback 
High Score 
Low Score General Fall Prevention Measures
Administrative Databases
System level:
Monitor Prescription Trends, Quality 
Improvement 
•Intensive Fall Prevention Measures
Patient level :
Diagnosis and Intervention: 
•Comprehensive Medication Review
•Modified MAI, etc
•Medication optimization 
 
 
This two-stage model for a Fall Specific Inappropriate 
Prescribing Assessment Tool (FASPIP) would have the 
advantage of using a screening tool which is user friendly and 
time-efficient, followed by a more complex and laborious 
tool. This approach would yield a risk stratification of patients 
according to their level of risk of falling, which could further 
be integrated with existing risk assessment tools involving 
other falls related risk factors.     
 
This model would capitalize on the advantages of both types 
of criteria. Additionally, in contrast with a static approach 
using lists such as the Beers Criteria, prescriber involvement 
(with a target MAI-based assessment) in real time is 
important, as most culprit drugs are “potentially 
inappropriate” and individual patients may legitimately 
necessitate a particular drug [41]. Additionally, prescriber 
feedback is crucially important, as the ultimate goal of a 
quality development initiative, is improving prescribing 
appropriateness. Active multifaceted strategies, feedback 
from peers and “real-time” reminders are recognized as 
among the few strategies which are potentially effective in 
influencing prescriber behavior [42]. Not only is feedback an 
effective behavioral tool, but a comprehensive medication 
review and reconciliation would also offer prescribers the 
much needed  “real time” rational alternatives, which, in 
turn, will support the adoption of the screening tool [36] [41].  
 
The development of a Screening Tool would require an 
extensive (re)consideration of its evidence–based support  
(Figure 2). Such a tool could be developed and then 
dynamically updated as evidence cumulates. Even with 
current IT advances this task may be within reach.   
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Figure 2. An evidence-based framework for developing a falls specific medication IP tool 
CANDIDATE drugs. Compile an evidence-based -driven list of ‘risky’ drugs. 
(explicit criteria). Categorize according to risk level into a Medication Fall Risk 
Score.  
Developing a Medication Fall Risk Score. An Evidence- based Framework 
Is it VALID?
•Test the validity against a gold standard , 
establish its Se, Sp, PPV, NPV in various settings 
(in-hospital, community dwelling elderly, 
nursing homes, etc) 
•Determine optimum cut off point
Is it RELIABLE? 
Test the Reliability
•intra-rater 
•Inter-rater  
•Are its properties robust  
to various settings? 
Is it sensible to CHANGE?Is it associated with OUTCOMES?
Can it be incorporated into longitudinal 
SURVEILLANCE systems in order to support 
monitoring the effectiveness and impact of policies 
and programs?
Does it DISCRIMINATE between patients who need 
intervention and patients who do not? Does it discriminate  
between low and high quality prescribing?
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We have completed the first step in this approach, i.e. the 
evidence based selection of candidate drug. This listing would 
need to be dynamically updated. Additionally, the candidate 
drugs may need to be assessed for their risk level determined 
by available evidence. Sources of information would be 
systematic reviews, rating the available evidence using a 
standardized taxonomy, rather than expert opinions and 
integrating meta-analyses, such as the ones on drugs in older 
people conducted for psychotropic [21] and cardiac and 
analgesic drugs [43].
 
 
The determination of risk level is important, as not all drugs 
have the same risk profile in increasing the risk for falls. Drugs 
such as antidepressants, antipsychotics, sedatives/hypnotics, 
and opiate analgesics  have the highest risk; medication such 
as digoxin, diuretics, class 1A antiarrhythmics, sedating 
antihistamines, anticonvulsants (not including 
benzodiazepines and barbiturates), may be associated with a 
moderate risk of falling. Efforts have already being taken in 
this direction, yet their further development, dissemination 
and adoption seem to be lagging. For example, a medication 
classification based on their level of increasing the falls risk 
has been proposed by Beasley and Patatanian in 2009 [44]. 
These authors suggest that a score greater than 6 may 
warrant further in depth- medication review. Yet, in order for 
such an instrument to be widely adopted as a screening tool, 
it needs to be tested for its validity and reliability, optimum 
cut off points need to be determined, and the association 
with clinical outcomes needs to be determined, as outlined in 
Figure 2.  Use of the literature alone for validation of a FASPIP 
is inadequate. Steps 2 and 3 of Figure 2 require further 
research. While the FASPIP was developed for hospitalized 
patients, the authors anticipate that the tool could be useful 
in other settings, including nursing homes.  
Summary and conclusion  
Patient falls are a high risk, high cost challenge for hospitals. 
The equilibrium between efficiently treating patients and 
avoiding falls is particularly elusive in older patients with 
multiple chronic diseases.  Medication assessment includes 
recommendations to discontinue medications, decrease the 
dosage, use other treatments with reduced falls risk, monitor 
laboratory values and educate patients on how to minimize 
the risk of falls. Risk reduction strategies should include 
involvement of pharmacists in falls risk medication 
assessment on admission, for any newly ordered 
medications, and at discharge with appropriate follow-up as 
above. 
 
Our study focused on improving the most commonly used IP 
tools for use as FASPIP. Based on the literature, we have 
added many additional high-risk medications and drug classes 
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to the criteria and simplified the MAI for use as a FASPIP. 
Combining a revised listing of medications which can cause 
falls with a revised MAI, we developed a FASPIP based on 
both explicit and implicit criteria for use in hospitalized 
elderly patients. 
 
Further research is needed to measure the impact of this 
FASPIP tool on physician prescribing habits and ultimately, fall 
reduction. Application in clinical practice is still to be 
extensively studied.  Comparing outcomes using the FASPIP 
vs. other tools could give us a rough idea to what extent the 
FASPIP is relevant in clinical practice to influence fall 
prevention. A continuous approach to falls prevention is 
ideal, and the goal is to update the FASPIP tool annually.   
Implications for hospital geriatric practice are vast. 
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Table 2 
Summary of Advantages and Disadvantages of Beer’s Criteria and MAI 
 
BEER’S CRITERIA MAI 
ADVANTAGES 
 Greatest experience and usage 
 Adopted by Federal quality regulators 
 Simple 
 Inexpensive 
 Applicable to all patients 
 Adaptable to computerized algorithms 
 Does not require information about indication for drug 
 May be assessed in large patient samples 
 
 
ADVANTAGES 
 Last updated in 2010 
 Applicable to every medication 
 Comprehensive 
 Focuses on the patient, not the drug 
 Good inter- and intra-rater reliability 
 Tested in both inpatient and ambulatory settings 
 Able to detect changes over time 
 Addresses multiple components of prescribing 
appropriateness 
 Applicable to every medication in the context of patient 
specific appropriateness 
 
DISADVANTAGES 
 Not updated for > 10 years 
 Not designed as a falls assessment tool 
 Limited reliability in a hospital setting 
 Incomplete 
 Not evidence-based 
 Usage of 3 lists can be confusing (conflicts with above) 
 Some drugs on list not even used in U.S. 
 Inaccurate- misses significant amount of inappropriate 
prescribing resulting in falls 
 Omits dosing, duration of therapy, drug interactions, 
polypharmacy considerations 
 
 
 
 
DISADVANTAGES 
 Complex 
 Not designed as a falls assessment tool 
 Requires comprehensive clinical data 
 Difficult to apply to large prescribing databases 
 Requires well trained health professional and 
interpretation by a skilled individual 
 Incomplete (e.g. does not assess causality) 
 No data available regarding predictive ability for falls 
 Burdensome- may take 10 minutes/drug to apply 
 Requires comprehensive clinical patient-specific 
information 
 Limited formal validity 
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Table 3.  Medications Associated With Falls in the Literature* 
*This list should be used in the context of a comprehensive clinical patient assessment and in consideration of the patient’s history 
and physical examination, laboratory assessment, and gait and balance assessment. 
 
Acarbose 
Acebutolol 
Acetazolamide 
Alprazolam 
Amiloride 
Amitriptyline 
Amlodipine 
Amobarbital 
Amoxapine 
Aripiprazole 
Asenapine 
Atenolol 
Atropine 
Azilisartan 
Baclofen 
Belladonna alkaloids 
Benzapril 
Benztropine 
Betaxolol 
Buspirone 
Bisprolol 
Bromcriptine 
Buchu 
Buprenorphine 
Butabarbital 
Butorphanol 
Bupropion 
Bumetanide 
Candesartan 
Captopril 
Carbamazepine 
Carisoprodol 
Cat’s claw 
Celecoxib 
Cetirizine 
Chloral hydrate 
Chlorazepate 
Chlordiazepoxide 
Chlorpheniramine 
Chlorpromazine 
Chlorpropamide 
Chlorothiazide 
Chlorthalidone 
Cimetidine 
Citalopram 
Clemastine 
Clevidipine 
Clonidine 
Clomipramine 
Clonazepam 
Clozapine 
Codeine 
Cyclizine 
Cyclobenzaprine 
Cyproheptadine 
Dandelion 
Desipramine 
Desloratidine 
Dexbrompheniramine 
Dexchlorpheniramine 
Dexmedetomidine 
Dimenhydrate 
Diazepam 
Diclofenac 
Dicyclomine 
Digoxin 
Diltiazem 
Diphenhydramine 
Diphenoxylate 
Disopyramide 
Divalproex sodium 
Doxazosin 
Doxepin 
Doxylamine 
Duloxetine 
Enalapril 
Eprosartan 
Escitalopram 
Esmolol 
Estazolam 
Ethacrynic acid 
Etomidate 
Ethosuximide 
Exenatide 
Eye drops 
Famotidine 
Felbamate 
Felodipine 
Fentanyl 
Fexofenadine 
Fluoxetine 
Fluphenazine 
Fluvoxamine 
Flurazepam 
Fosinopril 
Fosphenytoin 
Furosemide 
Gabapentin 
Glimepiride 
Glpizide 
Glyburide 
Glycopyrrolate 
Gotu Kola 
Guanabenz 
Guanethidine 
Guanfacine 
Haloperidol 
Hydrochlorthiazide 
Hydrocodone 
Hydromorphone 
Hydroxyzine 
Hyoscyamine 
Ibuprofen 
Imipramine 
Indapamide 
Indomethacin 
Insulin 
Irbesartan 
Isocarboxazid 
Isosorbide (mononitrate & 
dinitrate) 
Isradipine 
Ketamine 
Ketotifen 
Labetolol 
Lacosamimde 
Lamotrigine 
Levetiracetam 
Levocetirizine 
Levodopa/Carbidopa 
Levorphanol 
Licorice 
Linagliptin 
Liraglutide 
Lisinopril 
Lithium 
Loratadine 
Lorazepam 
Loxapine 
Maprotiline 
Meclizine 
Meperidine 
Methocarbamol 
Mesoridazine 
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Metalaxone 
Methyldopa 
Metoclopramide 
Metoprolol 
Methyldopa 
Methazolamide 
Metformin 
Methadone 
Methscopolamine 
Methsuximide 
Metolazone 
Miqlitol 
Minoxidil 
Mirtazapine 
Moexipril 
Molindone 
Morphine 
Nadolol  
Nalbuphine 
Naproxen 
Nateglinide 
Nebivolol 
Nefazodone 
Nicardipine 
Nifedipine 
Nimodipine 
Nitrates 
Nitrous Oxide 
Nitroglycerin 
Nizatidine 
Nortriptylline 
Olanzapine 
Olmesartan 
Opium tincture 
Orphenadrine 
Oxazepam 
Oxcarbazepine 
Oxybutynin 
Oxycodone 
Oxymorphone 
Pamabrom 
Paraldehyde 
Paroxetine 
Penbutolol 
Pennywort 
Pentazocine 
Pentobarbital 
Perphenazine 
Phenobarbital 
Phenyltoloxamine 
Phenytoin 
Pimozide 
Pindolol 
Pioglitazone 
Piroxicam 
Prazosin 
Pregabalin 
Primadone 
Procainamide 
Promethazine 
Propantheline 
Propofol 
Propranolol 
Protriptylline 
Quarazepam 
Quetiapine 
Quinapril 
Quinidine 
Ramapril 
Ranitidine 
Repaglinide 
Reserpine 
Risperidone 
Rosiglitazone 
Rufinamide 
Saxagliptin 
Scopolamine (systemic & 
ophthalmic) 
Secobarbital 
Selegline 
Sertraline 
Sevoflurane 
Sitagliptin 
Sotalol 
Spironolactone 
Stinging Nettle 
St. John’s Wart 
Sufentanil 
Telmisartan 
Temazepam 
Terazosin 
Thioridazine 
Thiopental 
Thiothixene 
Tiagabine 
Timolol (systemic & 
ophthalmic) 
Tizanidine 
Tolazamide 
Tolbutamide 
Tolerodine 
Topiramate 
Torsemide 
Trandolapril 
Tranylcypromine 
Trandolapril 
Trazodone 
Triamterene 
Trihexyphenidyl 
Trimipramine 
Tramadol 
Trifluperazine 
Tripelennamine 
Triprolidine 
Valproic acid 
Valsartan 
Venlafaxine 
Verapamil 
Yarrow 
Ziconotide 
Ziprasidone 
Zolpidem 
Zonisamide 
 
 
 
 
